YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA-Methylation Blood Test for Post-Treatment Breast Cancer Monitoring
YD Bio Limited - Ordinary Shares (YDES)
Company Research
Source: GlobeNewswire
Taipei, Taiwan, Nov. 05, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (NasdaqGM: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its support for the global commercialization of OkaiDx™, a research-use-only (RUO) blood test for post-treatment breast cancer monitoring now available through the Company’s affiliate EG Biomed US Inc. (“EG BioMed”)’s CLIA/CAP-certified laboratory in the United States. YD Bio’s role is to support commercialization efforts for OkaiDx™ under the authorization granted to the Company, working alongside EG BioMed to make the assay accessible to research laboratories, academic groups and industry partners conducting surveillance and translational studies. OkaiDx™ was developed through international scientific collaboration and uses cfDNA methylation profiling to generate molecular surveillance information for research settings. The test has been rep
Show less
Read more
Impact Snapshot
Event Time:
YDES
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
YDES alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
YDES alerts
High impacting YD Bio Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
YDES
News
- YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early DetectionGlobeNewswire
- YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome TherapeuticsGlobeNewswire
- YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDESGlobeNewswire
- YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities GlobeNewswire
- YD Bio Limited Reports Unaudited Half Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
YDES
Sec Filings
- 11/17/25 - Form 424B3
- 11/17/25 - Form 6-K
- 10/24/25 - Form F-1/A
- YDES's page on the SEC website